NewAmsterdam Pharma (NASDAQ:NAMS) Posts Earnings Results, Beats Expectations By $0.33 EPS

NewAmsterdam Pharma (NASDAQ:NAMS) posted its quarterly earnings data on Wednesday. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.33, FiscalAI reports. The business had revenue of $19.16 million for the quarter, compared to analyst estimates of $8.82 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS traded down $1.67 during trading hours on Thursday, hitting $19.26. 899,537 shares of the company’s stock were exchanged, compared to its average volume of 1,172,057. The business’s 50 day moving average is $22.43 and its 200-day moving average is $29.65. NewAmsterdam Pharma has a 12-month low of $19.00 and a 12-month high of $42.21. The firm has a market capitalization of $2.30 billion, a P/E ratio of -8.92 and a beta of 0.15.

Wall Street Analyst Weigh In

NAMS has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Sunday. Royal Bank Of Canada cut their price objective on shares of NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a research report on Monday, October 5th. BMO Capital Markets assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an “outperform” rating and a $58.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, October 15th. Finally, Jefferies Financial Group restated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $48.90.

Key NewAmsterdam Pharma News

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: The European Commission approved Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe), the first regulatory approvals worldwide for obicetrapib. The approvals mark a key regulatory milestone and open the door to European commercialization. Company announcement
• Positive Sentiment: Third-quarter results beat expectations: the company reported a loss of $0.14 per share versus the consensus estimate of a $0.47 loss, while revenue of $19.16 million exceeded estimates of $8.82 million. Reports also noted that the net loss narrowed and revenue grew year over year. Q3 results report
• Positive Sentiment: Stifel said it continues to view NAMS’ setup as “very compelling and significantly upside-biased,” signaling a favorable analyst view of the company’s prospects. Stifel analyst comments
• Negative Sentiment: Despite the earnings beat, NewAmsterdam remains loss-making, so investors may continue to focus on its ability to turn regulatory progress into sales and reduce ongoing losses.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, Director John W. Smither sold 1,600 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the transaction, the director directly owned 8,760 shares in the company, valued at $221,803.20. This represents a 15.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael H. Davidson bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average cost of $22.65 per share, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer directly owned 792,923 shares of the company’s stock, valued at approximately $17,959,705.95. The trade was a 1.28% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 176,846 shares of company stock worth $4,661,919 in the last 90 days. 12.74% of the stock is owned by company insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.